BaroFold’s mission is to improve the tolerability, efficacy and safety of protein therapeutics utilizing its proprietary PreEMT™ technology. The Company is focused on chronic indications in which there is significant patient and physician demand for better treatment options.

A Revolution in Protein Therapy

BaroFold is a privately held biopharmaceutical company focused on the development of commercially attractive protein therapeutics for immunology indications.  The company’s goal is to discover, develop and commercialize protein biologics, some of which incorporate its proprietary PreEMT™ high pressure folding technology along with other state-of-the-art technologies. This pipeline contains therapeutics with an Immunology focus, including Multiple Sclerosis, Rheumatoid Arthritis, and Asthma.

BaroFold’s development candidates target chronic indications having significant physician and patient demand for therapies that are more tolerable and efficacious than those currently available. 

BaroFold is well funded and has leveraged its unique technology to form relationships with several biopharmaceutical companies including Genentech, Pfizer, Eli Lily and others. The company closed on its Series A institutional financing in May 2007, raising US$12 million from seasoned healthcare investors, including Boulder Ventures and HBM BioVentures.